Diagnostic Value of Exome and Genome Sequencing As Well As Conventional Methods in Rare Diseases and Familial Tumor Syndromes
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Rare Diseases
- Sponsor
- University Hospital Tuebingen
- Enrollment
- 12000
- Locations
- 1
- Primary Endpoint
- Diagnosis
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
For the retrospective data analysis, patients with genetic diseases of any age and, if available, other family members, for whom genetic analyzes were carried out between 10/2016 and 12/2020, should be included. This equates to approximately 13,000 records, minus combined analyzes in the same patient, an estimated 12,000 individuals.
Detailed Description
The methodological developments of the last few years allow the broad use of next-generation-sequencing (NGS) -based methods in the routine molecular genetic diagnosis of genetic diseases.The aim of the retrospective data analysis is to create a solid data basis for further discussion regarding the development and mapping of diagnostic algorithms and subsequent supply routes. For the genome data, this evaluation is to be expanded to include the evaluation of the Polygenic risk scores (PRSs) in the sense of an additional finding.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient with genetic disease or
- •Family members
- •Genetic analysis between 10/2016 and 12/2020 at the Institute for Medical Genetics and Applied Genomics at the University Hospital Tübingen
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Diagnosis
Time Frame: Day 1
Number of established probable diagnosis using molecular genetic diagnostics